People · Operator
Named in public records as an officer, director or promoter · active 2020–2026 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $138.5M | $348.3M | 2026 |
| Rain Therapeutics Inc. | — | Biotechnology | Series C | $92.0M | $2.8B | 2020 |
Peter Radovich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Radovich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Mathers | 1 | 11 |
| Patrick Heron | 1 | 11 |
| Jonathan Leff | 1 | 11 |
| Michael Grey | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Patrick J. Heron | 1 | 7 |
| Franklin Berger | 1 | 7 |
| Edward T. Mathers | 1 | 3 |
| Laura Brege | 1 | 3 |
| Susan Dube | 1 | 3 |
| Gorjan Hrustanovic | 1 | 3 |
| Aaron Davis | 1 | 3 |
| William C. Fairey | 1 | 2 |
| Michael G. Grey | 1 | 2 |
| Niall J. O'Donnell | 1 | 1 |
| Laurent J. Fischer | 1 | 1 |
| Laura J. Brege | 1 | 1 |
| Christopher J. Peetz | 1 | 1 |
| Tiba J. Aynechi | 1 | 1 |
| Chris Peetz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.